Shows
Talking To Teens: Expert Tips for Parenting TeenagersEp 316: Educating Teens About CancerChadi Nabhan, author of The Cancer Journey, joins us to discuss how parents can talk to their teenagers about cancer, understand the common misconceptions, and best support teens when their peers or family members face a cancer diagnosis.Full Show NotesCancer is a challenging topic for families to discuss, especially when teenagers are involved. The fear, confusion, and misinformation surrounding cancer can make these conversations even more daunting. At some point, your teen might encounter a peer, teacher, or friend's family dealing with a cancer journey, and knowing how to communicate...2024-11-2524 min
Up For A ChatUC 405: The Cancer Journey With Dr Chadi NabhanCyndi and Kim sit down with Dr. Chadi Nabhan again, a renowned oncologist and hematologist with over 20 years of experience, to discuss his latest book, The Cancer Journey. Dr. Nabhan shares his motivation for writing the book: to offer guidance and support to patients and families navigating the complexities of cancer.
The conversation delves into the power of storytelling as a tool to simplify cancer-related topics, making them more accessible and relatable. Together, they explore key aspects of cancer, including its definition, causes, prevention, and the variety of treatment options available today.
Dr. Nabhan highlights...2024-11-211h 13
The HemOnc PulseDr. Usmani Highlights Myeloma Presentations from SOHO 2024On this episode of "The HemOnc Pulse," Saad Usmani, MD, of the Memorial Sloan Kettering Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss notable presentations on multiple myeloma from the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
2024-11-2025 minThe HemOnc PulseCovering MDS Updates at SOHO 2024 With Dr. VenugopalOn this episode of "The HemOnc Pulse," Chadi Nabhan, MD, MBA, FACP, is joined by Sangeetha Venugopal, MD, of the Sylvester Comprehensive Cancer Center at the University of Miami, to highlight data on myelodysplastic syndromes (MDS) presented at the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
2024-11-0125 min
Access Must-Have Full Audiobooks in Health & Wellness, Disorders & DiseasesThe Cancer Journey: Understanding Diagnosis, Treatment, Recovery, and Prevention by Chadi Nabhan Md Mba FacpPlease visithttps://thebookvoice.com/podcasts/1/audiobook/782987to listen full audiobooks.
Title: The Cancer Journey: Understanding Diagnosis, Treatment, Recovery, and Prevention
Author: Chadi Nabhan Md Mba Facp
Narrator: Chadi Nabhan Md Mba Facp
Format: Unabridged Audiobook
Length: 11 hours 49 minutes
Release date: October 15, 2024
Genres: Disorders & Diseases
Publisher's Summary:
A compassionate guide to the cancer journey, from screening and prevention to diagnosis and recovery.A cancer diagnosis can change our lives and the lives of our loved ones in an instant. It leaves us seeking answers to myriad questions and searching for hope. In The Cancer Journey, Dr. Chadi Nabhan demystifies this complex...2024-10-1511h 49Explore the Latest Full Audiobooks in Health & Wellness, Medicine & NaturopathyThe Cancer Journey: Understanding Diagnosis, Treatment, Recovery, and Prevention by Chadi Nabhan Md Mba FacpPlease visithttps://thebookvoice.com/podcasts/1/audiobook/782987to listen full audiobooks.
Title: The Cancer Journey: Understanding Diagnosis, Treatment, Recovery, and Prevention
Author: Chadi Nabhan Md Mba Facp
Narrator: Chadi Nabhan Md Mba Facp
Format: Unabridged Audiobook
Length: 11 hours 49 minutes
Release date: October 15, 2024
Genres: Medicine & Naturopathy
Publisher's Summary:
A compassionate guide to the cancer journey, from screening and prevention to diagnosis and recovery.A cancer diagnosis can change our lives and the lives of our loved ones in an instant. It leaves us seeking answers to myriad questions and searching for hope. In The Cancer Journey, Dr. Chadi Nabhan demystifies this complex...2024-10-1511h 49The HemOnc PulseAML News From SOHO 2024 With Dr. DaverOn this episode of "The HemOnc Pulse," Naval Daver, MD, of the MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss news on acute myeloid leukemia coming out of the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
2024-10-1123 minThe HemOnc PulseDr. Shadman Shares SOHO 2024 Data On CLLOn this episode of "The HemOnc Pulse," Mazyar Shadman, MD, MPH, of the Fred Hutchinson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to highlight some of the notable presentations on chronic lymphocytic leukemia coming out of the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
2024-09-2729 min
The ALL NEW Big Wakeup Call with Ryan GatenbyDr. Chadi NabhanSend us a textDr. Chadi Nabhan discusses his book THE CANCER JOURNEY: Understanding Diagnosis, Treatment, Recovery, and Prevention.Chadi Nabhan, MD, MBA, FACP, is a board-certified hematologist and a medical oncologist who practiced hematology and oncology for years. He has authored or co-authored over 300 peer-reviewed manuscripts and abstracts. He is the author of Toxic Exposure: The True Story behind the Monsanto Trials and the Search for Justice and is the creator and host of the weekly Healthcare Unfiltered podcast.2024-09-2712 min
The Lisa Wexler ShowA Holistic Way Of Treating CancerDr. Chadi Nabhan, MD, MBA, FACP joins Lisa Wexler to discuss his new book: THE CANCER JOURNEY Understanding Diagnosis, Treatment, Recovery, and Prevention.2024-09-2614 minThe HemOnc PulseDr. Bose on MPN Highlights From SOHO 2024On this episode of "The HemOnc Pulse," Prithviraj Bose, MD, of the University of Texas MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss some of the important data on myeloproliferative neoplasms that were presented at the Twelfth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
2024-09-1726 minThe HemOnc PulsePart Two: The Question of MRD in CLL TherapyIn part two of this episode, Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center; Meghan Thompson, MD, of Memorial Sloan Kettering Cancer Center; and Alan Skarbnik, MD, of Novant Health, continue to explore the role of measurable residual disease (MRD) in the treatment of patients with chronic lymphocytic leukemia (CLL).
“The HemOnc Pulse” was live for in Chicago, Illinois, on May 3-4 and featured host Chadi Nabhan, MD, MBA, FACP, moderating panels of academic and clinical experts who delved into unanswered questions in various hematologic malignancies.
2024-08-2220 minThe HemOnc PulseDr. Osman on Identifying and Treating High-Risk MDSOn “The HemOnc Pulse,” Chadi Nabhan, MD, MBA, FACP, met with Afaf Osman, MD, an Assistant Professor at the University of Utah Huntsman Cancer Center, to discuss how high-risk myelodysplastic syndromes (MDS) are distinct from lower-risk classifications and how to approach treatment.
2024-08-0925 minThe HemOnc PulseDr. Rami Komrokji on Trends in Real-World MDS CareOn “The HemOnc Pulse,” Chadi Nabhan, MD, MBA, FACP, spoke with Rami Komrokji, MD, Vice Chair of the Malignant Hematology Department at Moffitt Cancer Center in Tampa, Florida, about the state of myelodysplastic syndromes (MDS) care. Moffitt Cancer Center is home to a large MDS database, with clinical information on nearly 6,000 patients, a trove of real-world MDS data.
2024-07-2528 minThe HemOnc PulsePart One: The Question of MRD in CLL TherapyPart one of this episode explores questions in measurable residual disease (MRD) and chronic lymphocytic leukemia (CLL) with Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center; Meghan Thompson, MD, of Memorial Sloan Kettering Cancer Center; and Alan Skarbnik, MD, of Novant Health.
“The HemOnc Pulse” was live for in Chicago, Illinois, on May 3-4 and featured host Chadi Nabhan, MD, MBA, FACP, moderating panels of academic and clinical experts who delved into unanswered questions in various hematologic malignancies.
2024-07-1835 minThe HemOnc PulseUnpacking Bispecifics at ‘The HemOnc Pulse’ Live Meeting“The HemOnc Pulse” was live for the first time in Chicago, Illinois, on May 3-4 and featured host Chadi Nabhan, MD, MBA, FACP, moderating panels of academic and clinical experts who delved into unanswered questions in a range of hematologic malignancies. As part of the program, Michael Bishop MD, of the University of Chicago, and Aaron Goodman, MD, of the University of California, San Diego, were joined by Rafael Fonseca, MD, of the Mayo Clinic, to hold a panel on bispecific therapies and explore unanswered questions related to them.
2024-05-2446 minThe HemOnc PulseDiscussing the Role of MRD in CLL With Talal Hilal, MDDr. Hilal, of the Mayo Clinic, joins Chadi Nabhan, MD, MBA, FACP, on “The HemOnc Pulse” to discuss measurable residual disease (MRD) and the debates surrounding its use for response assessment in patients with chronic lymphocytic leukemia (CLL).
2024-05-1621 minThe HemOnc Pulse“The HemOnc Pulse” Live 2024 in Chicago: CAR-T Unanswered Questions“The HemOnc Pulse” goes on the road to Chicago May 3-4 with host Chadi Nabhan, MD, MBA, FACP, for the first live meeting.
This podcast episode features a panel discussion on unanswered questions in chimeric antigen receptor (CAR) T-cell therapy with Caron Jacobson, MD, MMSc, Medical Director of the Immune Effector Cell Therapy Program at Dana-Farber Cancer Institute; Michael Bishop, MD, FACP, FASCO, Director of the Hematopoietic Stem Cell Transplantation Program at the University of Chicago; Joseph Mikhael, MD, MEd, FRCPC, FACP, a Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Research Inst...2024-05-0538 minThe HemOnc Pulse"The HemOnc Pulse" Live 2024 in Chicago: AML Unanswered Questions"The HemOnc Pulse" goes on the road to Chicago with host Chadi Nabhan, MD, MBA, FACP.
This podcast episode features a panel discussion on unanswered questions in acute myeloid leukemia (AML) with Naval Daver, MD, an Associate Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center; Sanam Loghavi, MD, of the MD Anderson Cancer Center; Rami Komrokji, MD, the Vice-Chair of the Malignant Hematology Department at Moffitt Cancer Center in Tampa, Florida; and Mikkael Sekeres, MD, MS, a Professor of Medicine and Chief of the Division of Hematology at the Sylvester...2024-05-0434 minThe HemOnc PulseKrish Patel, MD, Talks Glofitamab, Other Novel Therapies in DLBCLDr. Patel, of the Swedish Cancer Institute in Seattle, Washington, joins Chadi Nabhan, MD, MBA, FACP, on “The HemOnc Pulse” to discuss novel frontline therapies in the lymphoma space, including the bispecific antibody glofitamab.
They also discuss bispecifics versus chimeric antigen receptor (CAR) T-cell therapy, fixed duration therapy and step-up dosing, and how to sequence therapy.
2024-04-0422 minThe HemOnc PulseAaron Goodman, MD, Tells Us the 'Crux' of Castleman DiseaseIn this episode of "The HemOnc Pulse," Dr. Goodman, an Associate Professor of Medicine at the University of California San Diego, joins Chadi Nabhan, MD, MBA, FACP, to discuss Castleman Disease.
Dr. Goodman explains why the rare disease is often mismanaged, how each subtype is diagnosed and treated, and how it's comparable to hematologic cancers like lymphoma or myeloma.
2024-04-0226 minThe HemOnc PulseIs MRD Negativity the New Benchmark in ALL Treatment Strategies?Elias Jabbour, MD, an Executive Editor of Blood Cancers Today and a Professor of Leukemia at the University of Texas MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss the function of measurable residual disease in treating acute lymphocytic leukemia (ALL) and other progress that has been made in treating patients with Philadelphia chromosome-positive and Philadelphia chromosome-negative ALL.
Dr. Jabbour also provides a brief historical perspective on tyrosine kinase inhibitors (TKIs), explaining how the therapies have improved survival outcomes in Ph+ ALL with or without transplantation.
2024-03-1419 min
The HemOnc PulseAditi Shastri, MD: Clinicians Need to ‘Come Together’ on TP53-Mutated MDSThis episode features a conversation between Dr. Shastri, an Assistant Professor of Medicine at the Montefiore Einstein Comprehensive Cancer Center in the Bronx, New York, and The HemOnc Pulse host, Chadi Nabhan; MD; MBA; FACP; on the latest news in myelodysplastic syndromes (MDS), including the final readout from the COMMANDS trial and the clinical implications of TP53-mutated MDS.2024-01-1823 min
The HemOnc PulseDr. Usmani Discusses Perseus, IsKia, Data Plus More Myeloma UpdatesSaad Usmani, MD, MBA, FACP, Chief of the Myeloma Service at the Memorial Sloan Kettering Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, on The HemOnc Pulse to chat about the latest research in multiple myeloma from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition.
Dr. Usmani shares insights on the evolution in myeloma treatment since he first started practicing in the hematologic oncology space. He also reflects on the Perseus and IsKia trials, which were presented at ASH 2023.2023-12-1827 min
The HemOnc PulseJerald Radich, MD: AML Abstracts to Keep an Eye on at ASH 2023In this episode of The HemOnc Pulse, Jerald Radich, MD, of the Fred Hutchinson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, to discuss various abstracts on acute myeloid leukemia (AML) presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition. The conversation centered around menin inhibitors for the treatment of AML, the effect of measurable residual disease-positivity on transplantation outcomes, and whether age plays a role in transplantation.2023-12-1736 min
The HemOnc PulseJorge Cortes, MD, on Why Balance Is Key in CML TherapyDr. Cortes, who serves as Director of the Georgia Cancer Center at Augusta University, joins host Chadi Nabhan, MD, MBA, FACP, to chat about the “boom” in treatments for chronic myeloid leukemia (CML), and where he sees a need for balance.
Dr. Cortes discussed the evolution of tyrosine kinase inhibitors (TKIs) and the multiple generations of TKIs that are now available. Second-generation TKIs can lead to earlier and deeper responses than first-generation TKIs, he said, noting that this means patients receiving second-generation TKIs are more likely to be able to discontinue treatment.
“If I was diagnosed with CML, I would take a...2023-11-0223 min
Up For A ChatUC 378: Toxic Exposure with Chadi NabhanIn this podcast, Chadi Nabhan discusses his new book, TOXIC EXPOSURE: The True Story Behind the Monsanto Trials and the Search for Justice.
Chadi Nabhan, MD, MBA, is a board-certified hematologist and a medical oncologist who practiced oncology and treated lymphoma patients for years. He has over 300 peer-reviewed papers, abstracts, and book chapters. He has worked in diverse healthcare settings and is the creator and host of the Healthcare Unfiltered podcast.
You can find Dr Chadi Nabhan at:
https://chadinabhan.com/
chadi nabhan MD, MBA, FACP (@chadinabhan) / X (twitter.com)
http...2023-09-271h 04
The HemOnc PulseDr. Garcia-Manero on the Data Behind the Luspatercept ApprovalGuillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, live at the Eleventh Annual Meeting of the Society of Hematologic Oncology to discuss the phase III COMMANDS trial, the recent approval of luspatercept, and other developments in myelodysplastic syndromes (MDS) treatment and research.
Dr. Garcia-Manero spoke about the design of the phase III COMMANDS trial, which evaluated luspatercept versus epoetin alfa for the treatment of anemia in patients with lower-risk MDS who required red blood cell (RBC) transfusions but had not previously received an erythropoiesis-stimulating agent.
“The study is very interesting in...2023-09-1320 min
The HemOnc PulseBhavana Bhatnagar, MD, on the Molecular Revolution in AMLIn this episode of The HemOnc Pulse, Dr. Bhatnagar, an Associate Professor of Medicine at the West Virigina University Cancer Institute, reflects on how the molecular characterization of acute myeloid leukemia (AML) has evolved. She joins host Chadi Nabhan, MD, MBA, FACP, to discuss how this growing base of knowledge has impacted diagnosis, treatment, and classification.
“The most significant changes have come about as a result of improvements and refinements in the molecular characterization of AML,” Dr. Bhatnagar said.
Some of these changes include major updates in the World Health Organization and European LeukemiaNet systems.
The episode also highlights Dr. Bhat...2023-08-1025 min
The HemOnc PulseAbi Vijenthira, MD, and Anca Prica, MD, on Why Certain DLBCL Therapies May Not Be Cost EffectiveDrs. Vijenthira and Prica, both of the Princess Margaret Cancer Centre, speak with host Chadi Nabhan, MD, MBA, FACP, about their analysis on the cost-effectiveness of pola-R-CHP and second-line CAR-T in patients with DLBCL, and why its results differed from a similar study published in the journal Blood in December 2022.2023-05-1832 min
The HemOnc PulseSagar Lonial, MD, FACP, on Why This MRD Approach Is ’Premature’ in MMBlood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, discusses how he approaches frontline therapy for multiple myeloma (MM), why he thinks certain approaches to minimal residual disease (MRD) in MM are “premature,” and the data that show why sustained MRD negativity is key, with host Chadi Nabhan, MD, MBA, FACP.2023-05-0422 min
The HemOnc PulseAlan Skarbnik, MD, Gives the Lowdown on Treating Patients with Follicular LymphomaAlan Skarbnik, MD, of Novant Health, discusses treating patients with follicular lymphoma, the nuances involved in those decisions, and why bispecifics are here to stay, with host Chadi Nabhan, MD, MBA, FACP.2023-04-2032 min
The HemOnc PulseAmer Zeidan, MBBS, MHS, on the Evolution of AML Classification, TreatmentIn this episode of The HemOnc Pulse, Amer Zeidan, MBBS, MHS, of Yale, discusses the impact of AML classification updates, the practical implications of testing for genetic alterations, and how patient characteristics inform his approach to treating AML, with host Chadi Nabhan, MD, MBA, FACP.2023-04-0626 min
the Essential Free Audiobooks in Non-Fiction, Current Affairs, Law, & PoliticsToxic Exposure: The True Story behind the Monsanto Trials and the Search for Justice by Chadi Nabhan Md Mba FacpPlease visit https://thebookvoice.com/podcasts/1/audiobook/646579 to listen full audiobooks. Title: Toxic Exposure: The True Story behind the Monsanto Trials and the Search for Justice Author: Chadi Nabhan Md Mba Facp Narrator: Chadi Nabhan Md Mba Facp Format: Unabridged Audiobook Length: 10 hours 39 minutes Release date: February 28, 2023 Ratings: Ratings of Book: 5 of Total 1 Genres: Current Affairs, Law, & Politics Publisher's Summary: For years, Monsanto declared that their product Roundup, the world’s most widely used weed killer, was safe. But that all changed in 2015, when the International Agency for Research on Cancer (IARC) analyzed data from scientific studies and concluded that gl...2023-02-2805 min
Grab the Essential Full Audiobooks in Non-Fiction, Current Affairs, Law, & PoliticsToxic Exposure: The True Story behind the Monsanto Trials and the Search for Justice by Chadi Nabhan Md Mba FacpPlease visithttps://thebookvoice.com/podcasts/1/audiobook/646579to listen full audiobooks.
Title: Toxic Exposure: The True Story behind the Monsanto Trials and the Search for Justice
Author: Chadi Nabhan Md Mba Facp
Narrator: Chadi Nabhan Md Mba Facp
Format: Unabridged Audiobook
Length: 10 hours 39 minutes
Release date: February 28, 2023
Ratings: Ratings of Book: 5 of Total 1
Genres: Current Affairs, Law, & Politics
Publisher's Summary:
For years, Monsanto declared that their product Roundup, the world’s most widely used weed killer, was safe. But that all changed in 2015, when the International Agency for Research on Cancer (IARC) analyzed data from scientific studies and concluded that glyphosate, th...2023-02-2810h 39
The HemOnc PulseLaurie H. Sehn, MD, MPH, on the Game-Changing Bispecifics in Follicular LymphomaIn the latest episode of The HemOnc Pulse, Laurie H. Sehn, MD, MPH, Chair of the Lymphoma Tumour Group at the BC Cancer Centre for Lymphoid Cancer, talks with host Chadi Nabhan, MD, MBA, FACP, about which bispecific antibodies will change the game in follicular lymphoma treatment. Dr. Sehn also explains why the TRIANGLE study is anticipated to be practice-changing and how it may make upfront transplant obsolete in MCL.2023-02-0937 min
The HemOnc PulseSanam Loghavi, MD, Tells Us Why 2022 was a Major Year for MDSSanam Loghavi, MD, stops by The HemOnc Pulse and chats with host Chadi Nabhan, MD, MBA, FACP, about why she thinks 2022 was a major year for MDS in this latest episode of the podcast. With the unveiling of the two new MDS classification systems in the past year, Dr. Loghavi breaks down the classification models and what it means for the specialty.2023-01-2639 min
The HemOnc PulseElizabeth Brem, MD, on Which CLL Abstract From ASH 2022 Can’t Be IgnoredIn the latest episode of The HemOnc Pulse, podcast host Chadi Nabhan, MD, MBA, FACP, talks with Elizabeth Brem, MD, Clinical Associate Professor in the School of Medicine at the University of California, Irvine, off the heels of the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition. Dr. Brem discusses which chronic lymphocytic leukemia (CLL) abstracts from ASH 2022 cannot be ignored, the latest news in Richter’s transformation, and why she is moving away from ibrutinib in her own clinical practice.2023-01-1236 min
The HemOnc PulseDrs. Hagop Kantarjian and Elias Jabbour Discuss Important AML, ALL Updates From ASH 2022In the inaugural episode of The HemOnc Pulse, podcast host Chadi Nabhan, MD, MBA, FACP, talks with Hagop Kantarjian, MD, and Elias Jabbour, MD, both of the Department of Leukemia at the University of Texas MD Anderson Cancer Center. The trio cover high-impact studies, novel treatment strategies, and controversial standard-of-care approaches for AML as well as ALL that were presented at the 2022 American Society of Hematology Annual Meeting & Exposition.2022-12-1444 min
Healthcare UnfilteredComplexities of Designing Clinical TrialsOn this special episode, Chadi hosts three phenomenal physicians to help us better understand the complexity of designing and executing clinical trials. Hira Mian, MD, faculty of health sciences, McMaster University (Canada), and Murali Janakiram, MD, MS, assistant professor, City of Hope, both faced and continue to face challenges in bringing their clinical trial ideas to light. Saad Usmani, MD, MBA, FACP, chief of myeloma service, Memorial Sloan Kettering Cancer Center, joins as a senior investigator to shed light on the journey and to advise both junior faculty on what can be done next. The group reacts to trial ideas...2022-07-121h 23